Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes

Completed

• Conditions: Epiretinal Membrane; Age Related Macular Degeneration

• Registration Number: NCT01846351
• Lead Sponsor: New England Retina Associates

Brief Summary

Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Detailed Description

Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Study Timeline

• Study Start: 2006-07
• Primary Completion: 2010-02
• Study Completion: 2010-02
• Status Verified: 2013-05
• Study First Submitted: 2013-05-01
• Study First Submitted QC: 2013-05-01
• Last Update Submitted: 2013-05-01
• Study First Posted: 2013-05-03
• Last Update Posted: 2013-05-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Significant epiretinal membrane
• Anti-VEGF treatment for age-related macular degeneration

Exclusion Criteria

• Uveitis
• Macular disorders
• Diabetic retinopathy
• Vascular occlusions

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best corrected visual acuity	12 months	Evaluate the best visual acuity during the follow up.
Central macular thickness	12 months	Evaluation of the retinal thickness changes with anti-VEGF treatment
Fluorescein angiogram	12 months	Evaluation of changes in lesion size during follow-up.